Beta2-adrenoreceptor agonist clenbuterol produces transient decreases in alpha-synuclein mRNA but no long-term reduction in protein

Abstract β2-adrenoreceptor (β2AR) agonists have been associated with a decreased risk of developing Parkinson’s disease (PD) and are hypothesized to decrease expression of both alpha-synuclein mRNA (Snca) and protein (α-syn). Effects of β2AR agonist clenbuterol on the levels of Snca mRNA and α-syn p...

Повний опис

Збережено в:

Бібліографічні деталі
Автори:	Joseph R. Patterson, Warren D. Hirst, Jacob W. Howe, Christopher P. Russell, Allyson Cole-Strauss, Christopher J. Kemp, Megan F. Duffy, Jared Lamp, Andrew Umstead, Michael Kubik, Anna C. Stoll, Irving E. Vega, Kathy Steece-Collier, Yi Chen, Anne C. Campbell, Catherine L. Nezich, Kelly E. Glajch, Caryl E. Sortwell
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Nature Portfolio 2022-05-01
Серія:	npj Parkinson's Disease
Онлайн доступ:	https://doi.org/10.1038/s41531-022-00322-x
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Beta2-adrenoreceptor agonist clenbuterol produces transient decreases in alpha-synuclein mRNA but no long-term reduction in protein

Схожі ресурси